Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine

Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine. Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor. We report the data from two phase I studie...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical pharmacology and therapeutics Ročník 103; číslo 5; s. 815
Hlavní autoři:	de Hoon, Jan, Van Hecken, Anne, Vandermeulen, Corinne, Yan, Lucy, Smith, Brian, Chen, Jiyun Sunny, Bautista, Edgar, Hamilton, Lisa, Waksman, Javier, Vu, Thuy, Vargas, Gabriel
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.05.2018
Témata:	Adolescent Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Calcitonin Gene-Related Peptide - metabolism Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use Double-Blind Method Female Healthy Volunteers Humans Male Middle Aged Migraine Disorders - drug therapy Migraine Disorders - metabolism Signal Transduction - drug effects Young Adult
ISSN:	1532-6535, 1532-6535
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!